Overview

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.
Phase:
Phase 3
Details
Lead Sponsor:
ThromboGenics